Abeona Therapeutics Inc. (NASDAQ:ABEO)‘s stock had its “hold” rating reissued by equities researchers at Jefferies Group LLC in a research note issued on Friday. They currently have a $11.00 price target on the biopharmaceutical company’s stock. Jefferies Group LLC’s price objective points to a potential upside of 78.86% from the company’s previous close.

Several other equities analysts have also recently weighed in on the stock. Maxim Group set a $14.00 price target on shares of Abeona Therapeutics and gave the company a “buy” rating in a research report on Tuesday, October 25th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $21.00 price target on shares of Abeona Therapeutics in a research report on Friday, October 21st. Zacks Investment Research raised shares of Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a research report on Tuesday, January 31st. HC Wainwright set a $20.00 price target on shares of Abeona Therapeutics and gave the company a “buy” rating in a research report on Monday, February 6th. Finally, Rodman & Renshaw reaffirmed a “buy” rating and issued a $20.00 price target (up previously from $17.00) on shares of Abeona Therapeutics in a research report on Tuesday, February 7th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $15.18.

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Shares of Abeona Therapeutics (NASDAQ:ABEO) opened at 6.15 on Friday. The company’s market cap is $245.75 million. Abeona Therapeutics has a one year low of $2.05 and a one year high of $9.44. The stock’s 50 day moving average price is $5.18 and its 200-day moving average price is $5.48.

This piece of content was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this piece of content can be accessed at http://www.dailypolitical.com/2017/02/17/abeona-therapeutics-abeo-hold-rating-reiterated-at-jefferies-group-llc.html.

A number of large investors have recently bought and sold shares of ABEO. RTW Investments LLC purchased a new stake in Abeona Therapeutics during the third quarter valued at approximately $116,000. Ardsley Advisory Partners purchased a new stake in Abeona Therapeutics during the third quarter valued at approximately $120,000. A.R.T. Advisors LLC purchased a new stake in Abeona Therapeutics during the fourth quarter valued at approximately $117,000. Tudor Investment Corp Et Al purchased a new stake in Abeona Therapeutics during the fourth quarter valued at approximately $162,000. Finally, GLG Partners LP purchased a new stake in Abeona Therapeutics during the fourth quarter valued at approximately $186,000. Hedge funds and other institutional investors own 17.79% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.

5 Day Chart for NASDAQ:ABEO

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.